Compare Firy Inc. (FIRY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Sana Biotechnology Inc — how do they compare? Firy Inc. trades at $12.26 (market cap $199.80M), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: Sana Biotechnology Inc is far larger — about 4.2× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and Sana Biotechnology Inc for 23 Days on average.
| FIRY | SANA | |
|---|---|---|
Market Cap | $199.80M | $836.71M |
Volume | 92,993 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $13.10 | $5.92 |
52-Week Low | $2.28 | $2.68 |
Typical Hold Time | 13 Days | 23 Days |
Enterprise Value | $168.40M | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY (formerly Skillz Inc.) trades at $11.85, down 5.05% today, with a bullish technical signal from moving averages despite negative fundamental metrics. The company reported Q2 2026 revenue of $31.0 million but missed EPS expectations with a net loss. Recent developments include a $719 million legal victory against Papaya Gaming and the appointment of Marc Lasry to the board, though cash burn remains elevated at -$86.41M for 2025.
The outlook remains challenged by persistent losses and negative margins, but potential collection of the legal judgment could provide significant upside. Risks include execution on cost controls and uncertainty around Papaya Gaming debt settlement. Analyst sentiment is mixed with 20% buy ratings amid high volatility.
SANA Biotechnology trades at $2.72, down 1.09% with a bearish technical signal despite bullish oscillators. The company shows significant financial challenges with negative revenue, a net loss of $244.17 million in 2025, and negative cash flow. However, analyst sentiment remains positive with 82% buy ratings and recent conference presentations highlighting ongoing research in engineered cell therapies.
The outlook is highly speculative given the pre-revenue stage and substantial losses. Investment opportunity lies in the potential of SANA's biotechnology platform, but risks include cash burn, clinical trial outcomes, and competitive pressures. Wall Street maintains cautious optimism despite fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
